Retrospective review of carvedilol administration in 38 dogs with preclinical chronic valvular heart disease

https://doi.org/10.1016/j.jvc.2012.01.007Get rights and content

Abstract

Objectives

Report the effect of carvedilol administration on clinical and echocardiographic parameters and outcome in dogs with preclinical (ACVIM Stage B) chronic valvular heart disease (CVD).

Animals, materials and methods

Retrospective case series of 38 client-owned dogs.

Demographic, physical examination and diagnostic imaging findings, blood pressure (BP), administration details and outcome were obtained from medical records of dogs receiving carvedilol for preclinical CVD. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners.

Results

Baseline data and follow-up were evaluated. Median and interquartile range (IQR) for age and weight were 8.6 (7.2–10.8) years and 8.5 (7.6–9.6) kg. 14/38 were male; 33/38 were Cavalier King Charles Spaniels; 33/38 had Stage B2 CVD. The initial dose of carvedilol was 0.31 (0.26–0.35) mg/kg PO twice daily. The carvedilol dose achieved following up titration was 1.11 (0.81–1.32) mg/kg twice daily. No adverse effects were recorded during up titration. Median survival for all dogs was 48.5 months with a 95% CI of 38.3–58.6.

Conclusions

This study suggests that carvedilol at the dose reported herein is well tolerated in small breed dogs with preclinical CVD. Prospective studies to evaluate efficacy are warranted.

Introduction

Chronic valvular heart disease (CVD) is the most common etiology of both heart disease and congestive heart failure (CHF) in the dog.1 The incidence increases with age in all dogs but small breed dogs, in particular the Cavalier King Charles Spaniel (CKCS), have increased risk.2 CVD is characterized by a long preclinical period. Based on the classification scheme presented in the American College of Veterinary Internal Medicine (ACVIM) Consensus Statement guidelines on the diagnosis and treatment of CVD, dogs with preclinical CVD are categorized as Stage B.3 Prior to the onset of cardiac remodeling, dogs with preclinical CVD are classified as Stage B1. Dogs are classified as Stage B2 once remodeling has progressed to an extent that can be readily detected by radiography and/or echocardiography. Progressive remodeling and the attendant neuroendocrine activation are associated with the development of CHF (Stage C) in some but not all dogs with Stage B CVD.4, 5, 6 A timely effective therapeutic intervention in dogs with Stage B CVD has the potential to delay the onset of CHF and prolong survival.

Currently there is no definitive proof that any medication initiated in either Stage B1 or B2 CVD can delay disease progression or improve survival. This lack of convincing evidence was reflected in the ACVIM Consensus Statement guidelines on the diagnosis and treatment of CVD; although this document did comment on the potential utility of both angiotensin converting enzyme inhibitors (ACEI) and beta-blockers (BB) in a subset of Stage B dogs.3 The reported benefits of chronic beta-blockade in models of chronic mitral regurgitation (MR) are likely multi-factorial and may involve limiting the consequences of chronic adrenergic stimulation on cardiomyocytes, changes in loading conditions and reductions in cardiomyocyte work related in part to reductions in heart rate (HR), indirect systemic systolic blood pressure (BP), left ventricular (LV) contractility and potentially regurgitant volume.7, 8, 9, 10

Carvedilol is a 3rd generation non-selective BB and alpha1-blocker with ancillary antioxidant effects and thus combines the potential benefit of non-selective beta-blockade with the afterload reduction properties of an alpha1-blocker. Additionally, the ancillary antioxidant properties may decrease oxidant stress associated with progressive heart failure.11

The Texas A&M University (TAMU) cardiology service routinely offers clients the option to initiate carvedilol administration once their dog is diagnosed with early or mild preclinical CVD. Dogs with substantial remodeling that are considered to be at imminent risk of CHF are typically excluded from this option. This retrospective review reports the outcome in a case series that had carvedilol initiated for preclinical CVD.

Section snippets

Animals, material and methods

The electronic medical records data base of TAMU Veterinary Medical Teaching Hospital was searched for all canine cases of Stage B CVD that received carvedilol between Jan 2002 and Jan 2011. Fifty dogs with Stage B CVD were identified as having received carvedilol. For the purpose of this study a diagnosis of Stage B1 CVD was defined as the presence of a characteristic murmur in a preclinical dog with a vertebral heart scale (VHS) ≤10.5. Stage B2 CVD was determined by the presence of a

Statistical analysis

Continuous variables are reported as median values, 25th–75th interquartile range (IQR), minimum and maximum value [range]. For each continuous variable, follow-up data are summarized in the same manner as the baseline. Paired baseline to follow-up comparisons were performed using the Wilcoxon matched-pairs signed-ranks test for medians and an exact McNemar’s test for proportions. Parametric survival models including Weibull, exponential and gamma, were evaluated by the use of Akaike’s

Baseline

The baseline study population consisted of 38 dogs. Dogs weighed 8.5 kg (7.6–9.6) [3.0–13.8] and 14/38 (36.8%) were males. The median age of all 38 dogs was 8.6 years (7.2–10.8) [3.0–12.8]. The majority of dogs were CKCS 33/38(86.8%). There was one each of Maltese, Cocker Spaniel, Pomeranian, Miniature Poodle and small mixed-breeds. All dogs had a murmur characteristic of MR and had no current or prior signs or symptoms of CHF. Five of 38 dogs (13.2%) had a VHS ≤10.5 and were categorized as

Discussion

There is emerging interest in evaluation of chronic beta-blockade for the treatment of moderate to severe chronic primary MR in human patients. In one retrospective study the use of beta-blockade was reported to have an independent survival benefit in human patients with chronic severe MR characterized by a normal LV ejection fraction however this has not been substantiated in prospective studies.15 One small pilot study8 reported that short-term treatment (14 days) with a beta-blocker (BB)

Conclusions

This study suggests that carvedilol at an initial dose of 0.31 mg/kg PO twice daily (0.26–0.35; range 0.15–0.53) and a target dose of 1.11 mg/kg twice daily (0.81–1.32; range 0.27–2.02) is safe and well tolerated in dogs with Stage B1 and early Stage B2 (normal LVIDs and LVIDs-N) if an up titration protocol is used that involves a 50–100% increase in dose every 7–14 days until the target dose is reached. Median survival for all dogs was 48.5 months with a 95% CI of 38.3–58.6. This study suggests

Acknowledgments

The authors would like to thank Kathy Glaze for her valuable work on this project.

References (30)

  • M. Borgarelli et al.

    Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease

    J Vet Intern Med

    (2008)
  • R.A. Stewart et al.

    Pilot study to assess the influence of beta-blockade on mitral regurgitant volume and left ventricular work in degenerative mitral valve disease

    Circulation

    (2008)
  • H. Tsutsui et al.

    Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation

    J Clin Invest

    (1994)
  • H. Yamakawa et al.

    Negative chronotropic effect of beta-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work

    Circulation

    (1996)
  • J.W. Buchanan et al.

    Vertebral scale system to measure canine heart size in radiographs

    J Am Vet Med Assoc

    (1995)
  • Cited by (8)

    • The influence of enalapril and spironolactone on electrolyte concentrations in Doberman pinschers with dilated cardiomyopathy

      2014, Veterinary Journal
      Citation Excerpt :

      The effect of pimobendan on the creatinine and potassium concentrations of the patients in our study is unknown. Our study is limited by the small number of dogs, the fact that a single breed of dog was studied, the different medication dosages used in this study compared to others (Bernay et al., 2010; Guyonnet et al., 2010; Gordon et al., 2012), and its retrospective nature. Given that we investigated a small number of Doberman pinschers, extrapolation of our results to other breeds with dilated cardiomyopathy should be exercised with caution.

    • Systolic arterial blood pressure in small-breed dogs with degenerative mitral valve disease: A prospective study of 103 cases (2007-2012)

      2013, Veterinary Journal
      Citation Excerpt :

      Some previous studies reported SABP only at the subclinical stage (Freeman et al., 2006; Tou et al., 2006; Jones et al., 2012), whereas others provided SABP in dogs with CHF due to MVD (Borgarelli et al., 2007; Nam et al., 2010) or cases of MVD pooled with cases of dilated cardiomyopathy (Cunningham et al., 2012). Some reports also documented SABP results when reporting the effects of therapeutic interventions (IMPROVE Study Group, 1995; Chetboul et al., 2007; Marcondes-Santos et al., 2007; Atkinson et al., 2009; Ouellet et al., 2009; Gordon et al., 2012; Peddle et al., 2012) or MVD prognosis (Borgarelli et al., 2008; Hezzell et al., 2010), but few reports have documented SABP values in dogs with MVD categorized by clinical (Nicolle et al., 2007; Schober et al., 2010) or echocardiographic staging (Ljungvall et al., 2010; Ljungvall et al., 2011; Moesgaard et al., 2012). Conversely, SABP variations in human acquired heart diseases are commonly documented, owing to the high prevalence of cardiovascular diseases in hypertensive people and the relationship between SABP values and survival in patients with ischemic or non-ischemic heart failure in the acute and/or chronic phases (Lee et al., 2006; Adamopoulos et al., 2007; Cheng et al., 2008; Buiciuc et al., 2011).

    View all citing articles on Scopus
    View full text